Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Uterine Fibroid Treatment Drugs Market
Based on drug class, the uterine fibroid treatment drugs market is segmented into progestin-releasing intrauterine device (IUD) & contraceptives, gonadotropin-releasing hormone (GnRH) antagonists, gonadotropin-releasing hormone (GnRH) agonists, non-hormonal medications, and other drug classes. Among the drug class, progestin-releasing intrauterine device (IUD) & contraceptives held significant market share of 65.7% in 2022 and is expected to growth at a CAGR of 9.9% over the coming years. The progestin-releasing intrauterine device (IUD)& contraceptives offers several advantages in managing the uterine fibroids, including reduced menstrual bleeding, pain relief, shrinking of fibroids, effective birth control and minimal side effects. In addition to this, this drug class provide long-term symptom relief as they remain effective for a long time and is suitable for women with different age groups. All these factors collectively aid in boosting the growth of this segment.
Based on the type, the uterine fibroid treatment drugs market is classified into submucosal fibroids, intramural fibroids, subserosal fibroids, and pedunculated fibroids. In 2022, the submucosal fibroids segment was valued to be USD 608.8 million and is expected to reach USD 1,589 million by 2032. Submucosal fibroids are particularly known for causing heavy menstrual bleeding, the progestins or GnRH agonists drug classes are widely used to manage the excessive bleeding by regulating hormones and controlling the growth of fibroids. During the forecast period, intramural fibroids are anticipated to grow at fastest CAGR as they can significantly contribute to infertility and pregnancy complications, hence treating such type of fibroids is crucial.
Based on the distribution channel, the uterine fibroid treatment drugs market is divided into retail pharmacies, hospital pharmacies, and other distribution channels. The retail pharmacies accounted for highest business share of 77.3% in 2022. The non-hormonal medications, contraceptives, NSAIDs, and other drugs are easily available in retail stores. Moreover, most of the patients with uterine fibroids are treated in outpatient settings except those who require surgery, leading to an increasing purchase of such drugs from retail pharmacies. Additionally, the availability of medications and increasing demand for safe and effective treatment in retail pharmacies is impacting the growth of retail pharmacies segment.
The North American uterine fibroid treatment drugs market is expected to grow at CAGR of 9.4% during the forecast period. Some of the factors contributing to the growth includes increasing prevalence of uterine fibroid, increasing demand for non-invasive, safe and effective treatment option, and better healthcare accessibility. Additionally, the presence of key players, approval of novel drugs, and increasing awareness related to the disease are expected to propel the market trends. The Asia Pacific region is expected to grow at highest CAGR of 10.9% during the forecast period because of the increasing prevalence of uterine fibroid in this region.